In the Tat-SH3GL2-treated group, however, PSD95, synaptophysin, and SNAP-25 levels were significantly higher in the hippocampus at 1 day and 4 days after ischemia compared to those in the Tat peptide or Control-SH3GL2-treated groups (Figure 5C). The gene discussed is SH3GL2; the disease is ischemia.